Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 394

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
Conditions:   Primary Central Nervous System Lymphoma;   Non-Hodgkin Lymphoma of Extranodal Site
Intervention:   Drug: PAXALISIB
Sponsors:   Lakshmi Nayak;   Kazia Therapeutics Limited

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 9, 2021 / by / in